Conference Proceeding | Published:

T2-relaxation mapping and fat fraction assessment to objectively quantify clinical activity in thyroid eye disease: an initial feasibility study

Abstract

Imaging in thyroid eye disease (TED) is used to exclude other diagnoses, assess for apical crowding and plan surgery. But to quantify TED activity objectively, subjective clinical scoring assessments remain the norm. Magnetic resonance imaging (MRI) T2-relaxation times correlate with extra-ocular muscle (EOM) inflammation, but are confounded by signal from fat. We investigated whether T2-relaxation mapping in combination with fat fraction (FF) measurements could quantify disease activity in EOMs objectively. Sixty-two TED patients and six controls were enroled for coronal short tau inversion recovery (STIR), T2 multi-echo fast-spin echo and multi-echo fast-gradient echo MRI of the orbits. STIR signal intensity ratios (SIRs), T2-relaxation times and percentage FF were derived for inferior, lateral, superior and medial recti bilaterally. Twelve patients were re-scanned following immunosuppressive treatment. The results found a positive correlation for all subjects between T2 and SIR (p < 0.001), but only mean T2 differed significantly between patients and controls (p < 0.001). We measured FF in EOMs for the first time and found it greater in TED (p < 0.001). There was also a significant reduction in mean T2 after treatment, with a corresponding reduction in the clinical activity score (CAS) in almost all patients. We show that T2-relaxation times differentiate between normal and inflamed EOMs and are responsive to treatment. Combined, uniquely, with FF measurement in EOMs, an objective, quantitative marker of inflammation in TED-affected muscles could be derived. T2-relaxation times mirrored improvements in CAS after treatment, occasionally preceding them. Rarely, they diverged, suggesting limitations in the CAS as a disease burden marker.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Additional information

License: The corresponding author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence on a worldwide basis to permit this article to be published.

References

  1. 1.

    Pitz S, Muller-Forell W. Orbital imaging. In: Wiersinga WM, Kahaly GJ, editors. Graves’ orbitopathy: a multidisciplinary approach—questions and answers. Basel, Karger; 2017. p 61–73.

  2. 2.

    Konuk O, Anagnostis P. Diagnosis and differential of Graves’ orbitopathy. In: Wiersinga WM, Kahaly GJ, editors. Graves’ orbitopathy: a multidisciplinary approach—questions and answers. Basel, Karger; 2017. p 74–92.

  3. 3.

    Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R. Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel approach. Br J Ophthalmol. 1989;73:639–44.

  4. 4.

    Gorman CA. The measuring of changes in Graves’ ophthalmopathy. Thyroid. 1998;8:539–43.

  5. 5.

    Dickinson AJ, Hintschich C. Clinical manifestations. In: Wiersinga WM, Kahaly GJ, editors. Graves’ orbitopathy: a multidisciplinary approach—questions and answers. Basel, Karger; 2017. p 1–25.

  6. 6.

    Dickinson AJ, Perros P. Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment. Clin Endocrinol (Oxf). 2001;55:283–303.

  7. 7.

    Dolman PJ. Grading severity and activity in thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2018;34 (4S Suppl 1):S34–40.

  8. 8.

    Werner SC. Modification of the classification of the eye changes of Graves’ disease: recommendations of the Ad Hoc Committee of the American Thyroid Association. J Clin Endocrinol Metab. 1977;44:203–4.

  9. 9.

    Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376:1748–61.

  10. 10.

    Roos JC, Murthy R. Personal communication. 2018.

  11. 11.

    Roos JCP, Paulpandian V, Murthy R. Serial TSH-receptor antibody levels to guide the management of thyroid eye disease: the impact of smoking, immunosuppression, radio-iodine, and thyroidectomy. Eye (Lond). 2018 Nov 6. https://doi.org/10.1038/s41433-018-0242-9. [Epub ahead of print].

  12. 12.

    Tortora F, Prudente M, Cirillo M, Elefante A, Belfiore MP, Romano F, et al. Diagnostic accuracy of short-time inversion recovery sequence in Graves’ ophthalmopathy before and after prednisone treatment. Neuroradiology. 2014;56:353–61.

  13. 13.

    Pajak M, Loba P, Wieczorek-Pastusiak J, Antosik-Biernaka A, Stefańczyk L, Majos A. Signal intensity and T2 time of extraocular muscles in assessment of their physiological status in MR imaging in healthy subjects. Pol J Radiol. 2012;77:7.

  14. 14.

    Mayer E, Herdman G, Burnett C, Kabala J, Goddard P, Potts MJ. Serial STIR magnetic resonance imaging correlates with clinical score of activity in thyroid eye disease. Eye. 2001;15:313–8.

  15. 15.

    Mancini L, Rajendram R, Uddin J, Lee RW, Rose GE, Yousry T, et al. Extra-orbital muscle T2 relaxation time and clinical activity in thyroid eye disease. In: Paper presented at International Society for Magnetic Resonance in Medicine. https://cds.ismrm.org/protected/10MProceedings/files/876_3843.pdf Accessed 28 Oct 2018.

  16. 16.

    Ohnishi T, Noguchi S, Murakami N, Tajiri J, Harao M, Kawamoto H, et al. Extraocular muscles in Graves ophthalmopathy: usefulness of T2 relaxation time measurements. Radiology. 1994;190:857–62.

  17. 17.

    Reeder SB, Sirlin CB. Quantification of liver fat with magnetic resonance imaging. Magn Reson Imaging Clin N Am. 2010;18:337–57–ix.

  18. 18.

    Hussain HK, Chenevert TL, Londy FJ, Gulani V, Swanson SD, McKenna BJ, et al. Hepatic fat fraction: MR imaging for quantitative measurement and display—early experience. Radiology. 2005;237:1048–55.

  19. 19.

    Politi LS, Godi C, Cammarata G, Ambrosi A, Iadanza A, Lanzi R, et al. Magnetic resonance imaging with diffusion-weighted imaging in the evaluation of thyroid-associated orbitopathy: getting below the tip of the iceberg. Eur Radiol. 2014;24:1118–26.

  20. 20.

    Mayer EJ, Fox DL, Herdman G, Hsuan J, Kabala J, Goddard P, et al. Signal intensity, clinical activity and cross-sectional areas on MRI scans in thyroid eye disease. Eur J Radiol. 2005;56:20–4.

  21. 21.

    Li H, Fitchett C, Kozdon K, Jayaram H, Rose GE, Bailly M, et al. Independent adipogenic and contractile properties of fibroblasts in Graves’ orbitopathy: an in vitro model for the evaluation of treatments. PLoS ONE 2014;9:e95586.

  22. 22.

    Lee BW, Kumar VB, Biswas P, Ko AC, Alameddine RM, Granet DB, et al. Transcriptome analysis of orbital adipose tissue in active thyroid eye disease using next generation RNA sequencing technology. Open Ophthalmol J. 2018;12:41–52.

  23. 23.

    Polito E, Leccisotti A. MRI in Graves orbitopathy: recognition of enlarged muscles and prediction of steroid response. Ophthalmologica. 1995;209:182–6.

  24. 24.

    Ozgen A, Alp MN, Ariyürek M, Tütüncü NB, Can I, Günalp I. Quantitative CT of the orbit in Graves’ disease. Br J Radiol. 1999;72:757–62.

  25. 25.

    Bijlsma WR, Mourits MP. Radiologic measurement of extraocular muscle volumes in patients with Graves’ orbitopathy: a review and guideline. Orbit. 2006;25:83–91.

  26. 26.

    Alp MN, Ozgen A, Can I, Cakar P, Gunalp I. Colour Doppler imaging of the orbital vasculature in Graves’ disease with computed tomographic correlation. Br J Ophthalmol. 2000;84:1027–30.

  27. 27.

    Kuo PH, Monchamp T, Deol P. Imaging of inflammation in Graves’ ophthalmopathy by positron emission tomography/computed tomography. Thyroid. 2006;16:419–20.

  28. 28.

    Di Maria C, Allen J, Dickinson J, Neoh C, Perros P. Novel thermal imaging analysis technique for detecting inflammation in thyroid eye disease. J Clin Endocrinol Metab. 2014;99:4600–6.

  29. 29.

    Tortora F, Cirillo M, Ferrara M, Belfiore MP, Carella C, Caranci F, et al. Disease activity in Graves’ ophthalmopathy: diagnosis with orbital MR imaging and correlation with clinical score. Neuroradiol J. 2013;26:555–64.

  30. 30.

    Lingam RK, Mundada P, Lee V. Novel use of non-echo-planar diffusion weighted MRI in monitoring disease activity and treatment response in active Grave’s orbitopathy: an initial observational cohort study. Orbit. 2018;37:325–30.

  31. 31.

    Laitt RD, Hoh B, Wakeley C, Kabala J, Harrad R, Potts M, et al. The value of the short tau inversion recovery sequence in magnetic resonance imaging of thyroid eye disease. Br J Radiol. 1994;67:244–7.

  32. 32.

    Kaichi Y, Tanitame K, Itakura H, Ohno H, Yoneda M, Takahashi Y, et al. Orbital fat volumetry and water fraction measurements using t2-weighted FSE-IDEAL imaging in patients with thyroid-associated orbitopathy. Am J Neuroradiol. 2016;37:2123–8.

  33. 33.

    Taoka T, Sakamoto M, Nakagawa H, Fukusumi A, Iwasaki S, Taoka K, et al. Evaluation of extraocular muscles using dynamic contrast enhanced MRI in patients with chronic thyroid orbitopathy. J Comput Assist Tomogr. 2005;29:115–20.

  34. 34.

    Sun B, Song L, Wang X, Li J, Xian J, Wang F, et al. Lymphoma and inflammation in the orbit: diagnostic performance with diffusion-weighted imaging and dynamic contrast-enhanced MRI. J Magn Reson Imaging. 2017;45:1438–45.

  35. 35.

    Jiang H, Wang Z, Xian J, Li J, Chen Q, Ai L. Evaluation of rectus extraocular muscles using dynamic contrast-enhanced MR imaging in patients with Graves’ ophthalmopathy for assessment of disease activity. Acta Radiol. 2012;53:87–94.

  36. 36.

    Guo Y, Huo L, Wang P, Huang L, Chai C, Sun F, et al. Evaluating the microcirculation of normal extraocular muscles using quantitative dynamic contrast-enhanced magnetic resonance imaging. J Comput Assist Tomogr. 2016;40:419–23.

Download references

Acknowledgements

We would like to acknowledge Dr. Paul Meyer, Dr. Nagui Antoun, and the MRI Radiographers.

Funding

The project was supported by the Addenbrooke’s Charitable Trust and the National Institute for Health Research [Cambridge Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust]. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

Author contributions

The team conceived of the idea for this study and all authors have contributed to the data gathering, analysis and writing.

Author information

Affiliations

  1. Department of Radiology, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke’s Hospital, Cambridge, UK

    • Tilak Das
    • , Andrew J. Patterson
    •  & Martin J. Graves
  2. Department of Ophthalmology, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke’s Hospital, Cambridge, UK

    • Jonathan C. P. Roos
    •  & Rachna Murthy
  3. Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK

    • Jonathan C. P. Roos
    •  & Rachna Murthy

Authors

  1. Search for Tilak Das in:

  2. Search for Jonathan C. P. Roos in:

  3. Search for Andrew J. Patterson in:

  4. Search for Martin J. Graves in:

  5. Search for Rachna Murthy in:

Conflict of interest

All authors are doctors who assess patients with thyroid eye disease either clinically or radiologically. There are no other conflict ofcompeting interests and a unified declaration form is available on request.

Ethics statement

This study was approved by the local Research Ethics Committee.

License

The corresponding author has the right to grant on behalf of all authors and does grant on behalf of all authors an exclusive licence on a worldwide basis to permit this article to be published.

Guarantor

Dr. Das serves as guarantor of this work. It is an honest, accurate and transparent account of the study being reported; no important aspects of the study have been omitted.

Corresponding author

Correspondence to Tilak Das.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/s41433-018-0304-z